Impact Biomedical IBO
NYSE IBO
$3.80 -0.31 (-7.54%)
At close: Oct 22, 2026 · 4:00 PM EDT

Impact Biomedical (IBO) FCF Margin (2023 - 2026)

Updated

Impact Biomedical's FCF Margin came in at 15666.67% for Q2 2026, up 25580.95 percentage points from -9914.29% a year earlier and up 22295.24 percentage points from the prior quarter.

Analysis

Impact Biomedical (IBO) FCF Margin (2023 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Impact Biomedical reported FCF Margin of -1451.43%, up 4448.57 percentage points year-over-year; for FY2022, it was -5036.00%.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Eli Lilly 1,230.11 Bn 1,198.70 Bn 19.71 Bn 33.76%
2 Johnson & Johnson 644.39 Bn 564.25 Bn 17.30 Bn 25.03%
3 AbbVie 503.52 Bn 476.68 Bn 12.70 Bn 18.33%
4 Merck 363.29 Bn 317.72 Bn 12.21 Bn 26.96%
5 Novartis Ag 298.23 Bn 262.62 Bn 11.24 Bn 38.60%
6 Astrazeneca 267.53 Bn 241.29 Bn 12.86 Bn 6.55%
7 Amgen 241.80 Bn 197.20 Bn 7.24 Bn 34.70%
8 Gilead Sciences 195.07 Bn 169.19 Bn 6.22 Bn 44.00%
9 Pfizer 173.33 Bn 120.28 Bn 10.94 Bn 2.01%
10 Impact Biomedical 409.72 Mn 412.92 Mn 2,000.00 15,666.67%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 15,666.67%
Mar 31, 2026 -6,628.57%
Dec 31, 2025 3,300.00%
Sep 30, 2025 -3,405.56%
Jun 30, 2025 -9,914.29%
Mar 31, 2025 -22,733.33%
Dec 31, 2024 -32,866.67%
Sep 30, 2024 -33,366.67%
Jun 30, 2024 -12,833.33%
Mar 31, 2024 -16,066.67%
Dec 31, 2023 -14,433.33%
Sep 30, 2023 -22,400.00%
API Access

Impact Biomedical FCF Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=fcf-margin&ticker=IBO&period=max&api_key=YOUR_API_KEY